Is Oncolytic Virotherapy a permanent cure for malignant gliomas?
AIDASCO Reviews · 2023
DOI: 10.59783/aire.2023.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift AIDASCO Reviews, 2023. Verfasst von Reshma Tendulkar und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Of all malignant glioma forms, glioblastoma is the most frequently present form. The treatment of this highly aggressive tumor form by applying conventional therapies is of low success, leading to a low survival rate. As representatives of immunotherapeutic agents, oncolytic viruses contribute to the revolution in cancer therapy. Although promising, the efficiency of oncolytic viruses for treating glioblastoma is also limited. This is a reason why further optimization of oncolytic virotherapy is necessary. In this work, we review some of glioblastoma's specificities and provide information about the current status of oncolytic virotherapy.
Zitieren
APA
Tendulkar, R., & Tendulkar, M. (2023). Is Oncolytic Virotherapy a permanent cure for malignant gliomas?. AIDASCO Reviews. https://doi.org/10.59783/aire.2023.12
Vancouver
Tendulkar R, Tendulkar M. Is Oncolytic Virotherapy a permanent cure for malignant gliomas?. AIDASCO Reviews. 2023. doi:10.59783/aire.2023.12
BibTeX
@article{Tendulkar2023,
author = {Tendulkar, Reshma and Tendulkar, Mugdha},
title = {Is Oncolytic Virotherapy a permanent cure for malignant gliomas?},
journal = {AIDASCO Reviews},
year = {2023},
doi = {10.59783/aire.2023.12}
}
EUVIMED